Future preclinical studies should focus on validating the safety and efficacy of selective Axl inhibitors in advanced GC models, assessing their interaction with chemotherapy and immunotherapy, and identifying biomarkers—such as EMT status, Axl/Gas6 expression, or circulating soluble Axl—for patient selection and response monitoring. The gene discussed is GAS6; the disease is gastric cancer.